Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2014—MyCartis announced the launch of Evalution, a digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic-acid-based biomarkers. Evalution provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.
December 2014—The Thermo Scientific XBF40 series of -40°C blast freezers are for rapid cooling during the sample preparation process, prior to freezer storage. Available in two options, the XBF40D-MD is designed for rapid plasma freezing and accommodates plasma bags, boxes, and bottles, and the XBF40D is for general-purpose applications and accommodates staggered loads and a variety of vessels, such as carboys, bottles, racks with vials, and more.
December 2014—EKF Diagnostics announced it has entered a two-year research collaboration with Massachusetts General Hospital to develop PointMan assays that can detect treatable cancer mutations in blood samples. MGH will use PointMan DNA for the detection of genetic variation in circulating tumor cells isolated from a patient’s blood using MGH’s CTC-Chip instrument.
December 2014—Streck’s A1c-Cellular Linearity, an HbA1c linearity/calibration verification material with intact red blood cells, is now assayed for the Trinity Biotech Premier Hb9210 and Ultra2 instruments. A1c-Cellular Linearity is a five-level assayed linearity material used to assess instrument accuracy and verify the patient reportable range of the HbA1c parameter.
December 2014—Horizon Discovery Group announced it has agreed to acquire Sage Labs for up to $16 million in cash and up to $32 million through the issue of new ordinary shares. The acquisition of Sage, a provider of next-generation research models, builds on the acquisition of CombinatoRx in July.
December 2014—To support users focused on hereditary disease, Qiagen has fully integrated Biobase HGMD Professional with Ingenuity Variant Analysis so that researchers no longer require a separate human gene mutation database license. The Ingenuity Variant Analysis is a Web-based software application that filters genetic variants in a secure, private, cloud-based environment to identify variants most likely to cause disease.
December 2014—Laboratories performing food and environmental testing, clinical research, forensic toxicology, pharmaceutical or biopharmaceutical measurements, and other applied analyses can now benefit from the performance of high-resolution accurate-mass (HRAM) Orbitrap mass spectrometry using an instrument designed for cost-per-sample-sensitive workflows.
December 2014—The PathScope 2 microscope imaging system from SPOT Imaging Solutions is designed to save pathologists up to two minutes per slide by streamlining routine slide examination. One click of the HistoSnap button captures the image during slide examination and imprints the image with the case number and reference mark, and then archives it to the laboratory information system, file server, or cloud storage.
December 2014—OvaGene Oncology announced it has entered into a research and development collaboration with Hitachi Chemical Research Center to bring novel mRNA-based signatures to the gynecologic oncology market. The collaboration is founded on Hitachi Chemical’s patented exosome technologies and OvaGene’s research, clinical validation, and translational focus.
December 2014—Omicia, a genome interpretation company, announced the commercial availability of Opal Clinical, the company’s software-as-a-service solution for diagnostic testing organizations. With Opal Clinical, users can launch NGS tests faster and interpret results more accurately and quickly, the company said in a statement.
